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BY-NC-ND license (http://creativecomAbstract Background: The emergence and spread of carbapenem-resistant Acinetobacter
baumannii poses a challenge for optimizing antibiotic therapies and preventing outbreaks.
Traditional phenotypic assays such as the modified Hodge test (MHT) or polymerase chain re-
action (PCR)-based detection of the carbapenemase genes are time-consuming and compli-
cated. Therefore, new approaches for the efficient detection of carbapenemase-producing
A. baumannii are urgently required.
Methods: In this study, we used the superficially porous liquid chromatography-tandem mass
spectrometry (LC-MS/MS) assay to measure carbapenem hydrolysis in a solution spiked with
test strains of A. baumannii. The rate of carbapenem hydrolysis during incubation was ex-
pressed as the ratio of the carbapenem peak area of the test A. baumannii strains to the
noncarbapenemase-producing A. baumannii ATCC 17978. This method can accurately measure
the carbapenem hydrolysis rate and, therefore, can effectively identify carbapenemase-
producing strains within 75 minutes.
Results: A total of 112 A. baumannii strains were used in this study, including 103 clinical iso-
lates with 68 carbapenem-resistant strains and 35 carbapenem-susceptible strains, seven ATCC
strains and two selected mutants. The results of the superficially porous LC-MS/MS assay
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Over the past few decades, multidrug-resistant (MDR) Aci-
netobacter baumannii has gradually emerged as an impor-
tant nosocomial pathogen worldwide.1 Carbapenems,
primarily imipenem and meropenem, have been used to
treat MDR A. baumannii infections.2 However, there are
increasing reports of carbapenem-resistant A. baumannii
being isolated.3,4 Previous studies showed that most
carbapenem-resistant A. baumannii isolates are able to
produce OXA-type (oxacillinase) carbapenemase.3,5 There-
fore, developing rapid and effective techniques for the
identification of carbapenemase-producing A. baumannii
will ensure appropriate treatment to patients, along with
effective control of nosocomial infections.
Conventional methods such as the modified Hodge test
(MHT) have successfully identified the majority of the
carbapenemase-producing bacteria,6 and commercial
phenotypic methods [e.g., the VITEK 2 system (bioMerieux,
Marcy L’Etoile, France)] are commonly used in microbiology
laboratories to identify carbapenem-resistant bacteria.
Previously, Pasteran et al7 proposed a procedure for car-
bapenem screening. They assumed that the clinical isolates
positively identified as carbapenemase producers would be
confirmed by additional, more specific methods such as the
MHT, together with the minimal inhibition concentration
(MIC) test. However, these additional methods are time-
consuming (typically >18 hours for the MHT and >4 hours
for the VITEK 2 system), relatively complicated to operate,
and may require specific media (e.g., the VITEK 2 system).
The Carba NP test is a colorimetric- and pH-based
detection of imipenem hydrolysis. Although it is a rapid
method to detect carbapenemase producers, it fails to
detect OXA-type carbapenemase, which is the most
frequently identified carbapenemase among the Acineto-
bacter species.8 Recently, carbapenemase-producing bac-
teria have been identified using a number of polymerase
chain reaction (PCR)-based methods.9,10 However, several
different enzyme families exhibit carbapenemase activity,
and the diversity of the genes encoding these enzymes has
limited the development of a single rapid test to identify all
carbapenemase-producing organisms.
Mass spectrometry (MS) technologies, such as matrix-
assisted laser desorption ionization time-of-flight MS
(MALDI-TOF MS) and ultra-performance liquid
chromatography-tandem MS (UPLC-MS/MS) are also able to
characterize carbapenemase-producing bacteria.11,12
MALDI-TOF MS can be used to detect molecules with a
broad range of masses. However, the small molecular size
of antibiotics (<1000 Da) complicates the analysis in two
ways; one is the possible interactions of the antibiotics with
the matrix, and the other is the interference from a highbackground signal.13 For example, meropenem can be
observed at a mass-to-charge ratio (m/z) of 383.4. The
dimer of alpha-cyano-4-hydroxycinnamic acid, a common
matrix, is observed at m/z 380. The peak of meropenem is
not clearly visible in a spectrum with a high matrix signal. In
contrast, LC-MS/MS, especially triple quadrupole MS/MS,
provides better spectral resolution and good quantification
performance in clinical chemistry laboratories.14 It is the
gold standard for determining small molecule compounds
because of its high sensitivity and specificity. In general, a
reduction in the particle size of the LC column leads to a
decrease in mass transfer and an increase in column effi-
ciency. Totally porous sub-2-mm particle LC columns pro-
vide high-resolution chromatography, but must be operated
at high back pressure.15 In recent years, sub-3-mm superfi-
cially porous columns, a solid core surrounded by a porous
layer, have been developed. The particle size distribution
of the superficially porous columns is significantly narrower
than that of the totally porous columns.16 The narrow
particle size distribution allows the formation of optimally
packed beds, consequently leading to high efficiency and
stability. Additionally, the superficially porous columns
exhibit column back pressure which is one-half to one-third
of that of the columns with totally porous sub-2-mm parti-
cles at the same flow rate, and they are potentially
compatible with the conventional high-performance LC in-
struments (back pressure limit, 400 bar).16,17 Moreover, the
re-equilibrium volume of a superficially porous column re-
quires less than three column volumes of the initiating
solvent, which reduces the analysis time.18 Therefore, in
this study, we chose to use a superficially porous column to
improve the separation efficiency.
In this work, we used superficially porous LC-MS/MS as-
says to measure carbapenem hydrolysis in a solution spiked
with the test strains of A. baumannii. Our results show that
this method can accurately measure the rates of carbape-
nem hydrolysis, and thus can effectively identify
carbapenemase-producing A. baumannii within 75 minutes.Materials and methods
Bacterial strains and growth conditions
The bacterial strains used in this study are summarized in
Table 1. Among the 112 strains of A. baumannii, seven
carbapenem-susceptible reference strains were obtained
from the American Type Culture Collection (ATCC), and two
were selected mutants generated from the parental strain
ATCC 17978. Sixty-eight carbapenem-resistant and 35
carbapenem-susceptible clinical isolates were non-
repetitively collected from three branches (Hualien,






MHT result of IPM Hydrolysis
rate of IPM (%)
ATCC17978 ATCC strain <2 e 0
ATCC15884 ATCC strain <2 e 0
ATCC15886 ATCC strain <2 e 0
ATCC19606 ATCC strain <2 e 0
ATCC15308 ATCC strain <2 e 0
ATCC15151 ATCC strain <2 e 0











determined by multiplex PCR
MIC (mg/mL)
of IPM
MHT result of IPM Hydrolysis
rate of IPM (%)
9 OXA-51 <2 e 0e40
1 OXA-51, TEM-1 <2 e 56
13 OXA-24, OXA-51 <2 e 0e37
1 OXA-24 <2 e 0
1 OXA-23, OXA-51 <2 e 0e21
10 All negative <2 e 0e14




determined by multiplex PCR
MIC (mg/mL)
of IPM
MHT result of IPM Hydrolysis
rate of IPM (%)Positive Negative
3 OXA-23, OXA-51, TEM-1 >8 2 1 100
1 OXA-24, OXA-51 >8 1 0 100
9 OXA-24, OXA-51, TEM-1 >8 9 0 100
34 OXA-51, TEM-1 >8 29 5 84e100
1 OXA-51, TEM-1 >8 0 1 19
16 OXA-51 >8 15 1 86e100
1 OXA-23, OXA-58, OXA-51, TEM-1 >8 1 0 100
2 OXA-23, OXA-51 >8 2 0 100
1 All negative >8 0 1 100
ATCC Z American Type Culture Collection; IPM Z imipenem; MHT Z modified Hodge test; MIC Z minimal inhibition concentration;
PCR Z polymerase chain reaction.
912 H.-R. Lin et al.Taipei, and Dalin) of the Buddhist Tzu Chi General Hospital
in Taiwan. All carbapenem-resistant clinical isolates
collected during 2007 were stored at 80C in trypticase
soy broth (Difco Laboratories, Detroit, MI, USA), supple-
mented with 20% glycerol, before testing. The isolates were
then transported to the clinical microbiology laboratory at
Tzu Chi University for further experiments. These bacteria
were cultured at 37C in brain heart infusion broth, ac-
cording to a standard protocol.
A. baumannii ATCC 17978 was used as a carbapenem-
susceptible parental strain to develop an LC-MS/MS assay
for carbapenemase detection that would be suitable for all
clinically relevant A. baumannii. The carbapenem-
borderline-susceptible and carbapenem-resistant selected
mutants were generated from the parental strain using a
method reported earlier.19 The selected strains exposed to
2 mg/L and 8 mg/L imipenem were collected during the
induction period and were referred to as 17978 IPM-2m and
17978 IPM-8m, respectively. The carbapenem susceptibilities of the selected mutants were tested using the broth
dilution method, according to the 2014 Clinical and Labo-
ratory Standards Institute (CLSI) guidelines.
Identification of strains and evaluation of
antimicrobial susceptibilities
A. baumannii strains used in this study were identified using
the Vitek system (bioMerieux). Bacterial resistance to car-
bapenem was double-checked using the broth dilution
method, in accordance with the 2014 CLSI guidelines. The
breakpoints for imipenem and meropenem as per these
guidelines were susceptible (S) 2 mg/L and resistant (R)
8 mg/L.
To detect the carbapenemase activity in A. baumannii
strains, MHT was performed as recommended by the CLSI.
Briefly, a 0.5 McFarland dilution of Escherichia coli 25922 in
5 mL of saline was prepared. A 1:10 dilution was inoculated
on the surface of a Mueller-Hinton agar plate and disks with
Rapid detection of carbapenemase in A. baumannii 913imipenem (10 mg) were placed onto the middle of the agar
plate. Test organisms were inoculated onto the plate in a
straight line from the disk to the edge of the agar plate. After
overnight incubation, the presence of E. coliwas interpreted
as a positive result for carbapenem hydrolysis screening.
Inhibition base test
According to Tsakris et al,20 both class A Klebsiella pneu-
monia carbapenemase (KPC) and class B metallo-b-lacta-
mases (MBLs) can be differentiated by a simple method
which can also detect the possible coproduction of both
carbapenemases. Briefly, the test was performed by inoc-
ulating Mueller-Hinton agar for the standard diffusion
method, then preparing one disc of imipenem without any
inhibitor and three discs of imipenem containing 400 mg of
phenylboronic acid (PBA), 292 mg of EDTA, or both 400 mg of
PBA and 292 mg of EDTA. The agar plates were incubated at
37C overnight. The diameters of the growth inhibitory
zone around the imipenem discs with inhibitors were
compared with the plain imipenem disc.
The hydrolysis rates of imipenem by clinical isolates
were detected with inhibitor added; methods are the same
as the LC-MS/MS sample preparation and instrumentation
described below.
Genotypic characterization of A. baumannii
isolates
There are many different enzyme families that exhibit
carbapenemase activity; therefore, it is difficult to screen
all potential targets in one single method. In this study, all
clinical isolates were analyzed for the presence of the
common oxacillinase genes (blaOXA-23, blaOXA-24, blaOXA-51,
blaOXA-58) and class A b-lactamase gene (blaTEM-1) using a
multiplex PCR method described by Ben et al.21
Chemicals and materials
Meropenem was purchased from the United States Phar-
macopeia. Imipenem and meropenem-d6 were obtained
from Toronto Research Chemicals (Molsheim, France).
Meropenem and imipenem were prepared in water, and
meropenem-d6 was prepared in methanol. All meropenem
and imipenem solutions were stored at 80C, without
multiple refreezing, for 1 month. Methanol was purchased
from Mallinckrodt (Phillipsburg, NJ, USA). Formic acid and
sodium hydroxide were purchased from Riedel-de-Hae¨n
(Seelze, Germany). All organic solvents and chemicals were
reagent grade.
Sample preparation for LC-MS/MS analysis
Each strain was injected into the LC-MS/MS system for the
detection of the hydrolysis of imipenem or meropenem.
The strains were cultured overnight on Mueller-Hinton agar.
The bacteria were suspended in normal saline with the
optical density at 600 nm (OD600) adjusted to 2 or 4. A 200-
mL volume of each suspension was incubated with 8 mg/mL
of imipenem or meropenem for 1 hour or 2 hours at 37C in
a 96-well microtiter plate under smooth agitation. Thesuspensions were then centrifuged at 12,000g for 5 mi-
nutes, and 100 mL of the supernatant was subsequently
mixed with 700 mL of methanol containing meropenem-d6
(1.5 mg/mL). After the centrifugation at 12,000g for 5 mi-
nutes, 200 mL of supernatant was mixed with 800 mL of
water for further LC-MS/MS analysis.
Instrumentation and LC-MS/MS parameters
The abundance of imipenem and meropenem was measured
using an LC-MS/MS system comprising a Thermo Accela LC
system (Thermo Fisher Scientific Inc., Waltham, MA, USA)
coupled to a TSQ Quantum tandem triple-quadrupole MS.
Chromatography separation was performed using a super-
ficially porous column (Agilent poroshell 120 EC-C18;
2.1 mm  100 mm, 2.7 mm). The flow rate was 0.32 mL/min
and the column temperature was set at 25C. The mobile
phase consisted of 0.1% formic acid in water (A) and 0.1%
formic acid in methanol (B). The gradient was as follows:
30% of component B at the time of injection was increased
linearly to 55% B over the first 0.3 minutes, and subse-
quently to 100% B over 1.5 minutes. This composition was
maintained for 0.2 minutes. At 1.9 minutes, the gradient
returned to the initial condition and was equilibrated for
1.6 minutes, resulting in a total run time of 3.5 minutes.
The injection volume was 10 mL. Ionization was achieved
using electrospray in positive ionization mode (ESIþ) with a
spray voltage of 2800 V. Nitrogen was used as the sheath
and auxiliary gas at 28 units and 2 units (arbitrary units).
The heated capillary temperature was 270C and the argon
collision gas pressure was 1 mTorr. The multiple-reaction-
monitored (MRM) parameters were optimized by post-
column infusion of the stock solution (1 mg/mL) using
Quantum Tune Master software (Thermo Fisher Scientific
Inc.). Optimal MRM parameters include tube lens (102 V for
imipenem and 107 V for meropenem) and collision energy
(27 eV for imipenem and 16 eV for meropenem). The
transitions of [MþH]þ precursor ion products were 383.9 m/
z to 141.2 m/z for meropenem, 300.1 m/z to 142.2 m/z for
imipenem, and 390.1 m/z to 147.1 m/z for the internal
standard (meropenem-d6). The scan time for each MRM
transition was set to 15 milliseconds. The hydrolysis rates of
imipenem and meropenem were calculated by dividing the
respective postincubation carbapenem concentrations by
that of the reference strain.
Results
Susceptibility testing
The antibiotic susceptibility results of all A. baumannii
strains used in this study are shown in Table 1. All of the A.
baumannii reference strains and carbapenem-susceptible
clinical isolates were susceptible to imipenem and mer-
openem (MIC < 2 mg/mL), and carbapenem-resistant clin-
ical isolates of A. baumannii were resistant to imipenem
and meropenem (MIC > 8 mg/mL). The MIC of the
imipenem-selected mutant 17978 IPM-2m to imipenem and
meropenem was 2 mg/mL. The MIC of the imipenem-
selected mutant 17978 IPM-8m to imipenem and mer-
openem was >8 mg/mL. Thus, 17978 IPM-2m was identified
914 H.-R. Lin et al.as a carbapenem-borderline-susceptible strain, and 17978
IPM-8m was identified as a carbapenem-resistant strain,
according to the 2014 CLSI guidelines.
Phenotypic and molecular screening
The MHT showed that 59 of the 68 carbapenem-resistant
clinical isolates possessed carbapenemase, and nine of the
clinical isolates had no sign of being able to hydrolyze imi-
penem (Table 1). According to the inhibitor base test, among
the 68 clinical carbapenem-resistant strains, 10 strains pro-
duced both KPC and MBL enzymes, four strains produced KPC
only, one strain produced MBL type, and the remaining 53
strains produced neither KPC nor MBL types. After defining to
which classes the clinical strains belonged, we chose several
strains to examine the hydrolysis rate with the inhibitors
added. We discovered that the clinical strains producing KPC
could be separated from other clinical strains by adding PBA.
Multiplex-PCR results showed that OXA-51 was detected
in most of the clinical isolates of A. baumannii, and TEM-1
was also detected in most of the carbapenem-resistant A.
baumannii isolates. Other genes such as OXA-23, OXA-24,
and OXA-58 were detected randomly in different isolates.
The gene distribution pattern does not match the classes
defined by the drug resistance results.
Development of superficially porous LC methods
for meropenem and imipenem
A rapid (3.5 minutes) and effective chromatographic sep-
aration was achieved using a sub-3-mm superficially porous
particle column in this study. The retention times of imi-
penem and meropenem were 0.81 minutes and 1 minute,
respectively (Figure 1). The bacteria were coincubated
with imipenem or meropenem in a 96-well microtiter plate
for large scale analysis. Protein precipitation was used in
the sample preparation in the current study to avoid the
degradation of imipenem and meropenem which was re-
ported in earlier studies.22,23 Protein precipitation mini-
mized the risk of instability of the drugs by quickly
removing the matrix. The effect of the matrix during the
extraction process was evaluated by comparing the peak
areas obtained for the target compounds in the culture
medium to those obtained for the target compounds in
water, in triplicate. Matrix enhancement or suppression,
expressed as a percentage, was measured using the ratio of
the mean peak area of the blank medium extract to that of
water. The matrix effects of imipenem and meropenem
were 73.5% and 89.2%, respectively. The matrix-match
calibration curves of imipenem and meropenem were
linear over a concentration range of 0.25e10 mg/mL, with a
correlation coefficient value > 0.9.
Optimization and validation of the superficially
porous LC methods
To develop an efficient method for the detection of carba-
penemase activity in A. baumannii, we optimized the assay
parameters, including drug concentration (0.25e10 mg/mL),
incubation time (1 hour or 2 hours), and bacterial inoculum
(OD600 Z 2 or 4). The effects of varying these parameterswere investigated using a set of three isolates derived from
the ATCC 17978-type strain, which were known to be sus-
ceptible, borderline-susceptible, and resistant to carbape-
nem. The incubation conditions are listed in Table 2. The
hydrolysis rates of imipenem andmeropenem increasedwith
an increase in the inoculums and the incubation time. The
hydrolysis rate of meropenem was slower than that of imi-
penem in the mutant 17978 IPM-2m. In order to enhance the
detection efficiency, an inoculum density of OD600Z 4 and
an incubation time of 1 hour were selected. Moreover, the
hydrolysis rate thresholds for carbapenemase-positive
strains were set to >75% for imipenem and >33% for mer-
openem. These thresholds were decided according to the
hydrolysis rate of carbapenem by 17978 IPM-2m (carbape-
nem-borderline-susceptible strain) at the lower inoculum
(OD600Z 2) and shorter incubation time (1 hour) (Table 2).
Our design was to establish a more stringent threshold to
avoid missing any carbapenemase-producing strains.
According to this optimization design, the mean hydro-
lysis rate of imipenem and meropenem in all carbapenem-
susceptible reference strains was <1%, and the mean hy-
drolysis rate in carbapenem-susceptible clinical isolates
was <9% (8.47% for imipenem and 8.04% for meropenem).
By contrast, among the 68 resistant strains, there were 67
strains that showed an average hydrolysis rate of 99%
(ranging from 84% to 100%) for imipenem and 68% (ranging
from 36% to 100%) for meropenem. Interestingly, among the
68 resistant strains, there was one strain which showed only
19% and 14% hydrolysis rates for imipenem and meropenem,
respectively. According to this result, we suspect the
carbapenem-resistant-mechanism of this clinical isolate
has no correlation with carbapenemase, but that another
mechanism leads to its resistance to carbapenem.
Comparing the results of the MHT and porous LC-MS/MS, we
discovered that of the nine clinical isolates which show no
sign of MHT, eight were found to produce carbapenemase,
suggesting that our LC-MS/MS method is more sensitive than
the MHT. The hydrolysis rates with inhibitor added can only
differentiate class A carbapenemase (data not shown). Our
results showed that using the thresholds determined as
described above, high agreement can be achieved with the
MIC result for the detection of carbapenem-resistant A.
baumannii (Table 1).Discussion
Imipenem-resistant A. baumannii bacteremia cause high
mortality which is associated with inappropriate initial
antimicrobial therapy. Rapid identification of imipenem-
resistant A. baumannii and early start of appropriate anti-
microbial therapy are crucial to reduce mortality in these
high-risk patients.24,25 In recent years, MS technologies such
as MALDI-TOF MS and LC-MS/MS have been applied to char-
acterize carbapenemase-producing bacteria,11,12,26 howev-
er, few studies have focused on carbapenemase-producing
A. baumannii.12,27 Most of these earlier studies differed in
the type of instrument used, the carbapenem used, the in-
cubation conditions, and the interpretive criteria. All of
these factors can affect the assay performance.
Carricajo et al11 reported the detection of
carbapenemase-producing bacteria using a UPLC-MS/MS
Figure 1. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) chromatograms for imipenem and meropenem for
reference strain A. baumannii ATCC 17978 and clinical isolate A. baumannii #08 (hydrolysis rate of imipenem is 100% and that of
meropenem is 87%). ESI Z electrospray; SRM Z selected reaction motoring; MA Z manual integration area; NL Z normalized
intensity level (counts per second); MSZ mass spectrometry, RT Z retention time; TIC FZ total ion chromatography (full scan).
Rapid detection of carbapenemase in A. baumannii 915method. In their study, the tested bacteria required incu-
bation for 3e4 hours, consuming a large amount of culture
medium and carbapenem solution. In order to decrease
costs while maintaining the detection efficiency, ourTable 2 Relationship between incubation condition and hydrol
A. baumannii strain MIC (range)
(mg/mL) OD600
IPM MEM IPM




ATCC 17978 IPM-8m (carbapenem- resistant) >8 >8 100
ATCC Z American Type Culture Collection; IPM Z imipenem; LC
MEM Z meropenem; MIC Z minimal inhibition concentration.method reduced the bacterial incubation volume to 200 mL,
and decreased the use of antibiotics to 8 mg/mL. Because
the incubation volume was reduced to 200 mL/sample, the
incubation procedure could be performed in a 96-wellysis rates.
LC-MS/MS hydrolysis rate (%)
Z 2, 1 h OD600 Z 2, 2 h OD600 Z 4, 1 h OD600 Z 4, 2 h
MEM IPM MEM IPM MEM IPM MEM
<1 <1 <1 <1 <1 <1 <1
33 97 56 100 66 100 100
100 100 100 100 100 100 100
-MS/MS Z Liquid chromatography-tandem mass spectrometry;
916 H.-R. Lin et al.microtiter plate. The incubation conditions, including
bacterial concentration and incubation time, were assessed
and the results are shown in Table 2. The bacterial incu-
bation density of OD600 Z 2 and an incubation time of 1
hour could sufficiently distinguish between the imipenem-
resistant and -susceptible strains. This optimized method
is not only cost-effective, but also feasible for large-scale
screening of carbapenemase-producing A. baumannii.
Using LC-MS/MS, Kulkarni et al26 determined carbape-
nemase activity within 75 minutes. Our method spends
approximately the same time, but only requires one-tenth
of the incubation volume. In addition, Kulkarni et al26
used three different columns for individually detecting
ertapenem, meropenem, and imipenem, which was time-
consuming, because of the switching between the col-
umns. Their system lacked sensitivity for detecting erta-
penem- and meropenem-resistant bacteria, although it
could efficiently identify imipenem-resistant bacteria
alone.26 In our method, only one superficially porous col-
umn was used to detect both meropenem and imipenem,
which efficiently detected carbapenemase in A. baumannii.
Porous LC-MS/MS has a high accuracy to detect the hy-
drolysis rate of A. baumannii against carbapenems. Using
this method, the hydrolysis rate of clinical A. baumannii
with a weak MHT result can be detected. The hydrolysis
rate is directly detected and would not be affected by the
genotype diversity, unlike molecular detection, thus mak-
ing it more efficient. We think the main disadvantage of this
method is that the initial cost of the equipment is high and
the operator needs to be well trained.
In conclusion, the average turnaround time, including
the incubation and analysis time for this method, was
estimated to be 75 minutes. Our study clearly demonstrates
that this superficially porous LC-MS/MS assay could be
routinely used in clinical microbiology laboratories to
identify carbapenemase-producing A. baumannii strains.
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